Pahul Singh, MD
Interventional Cardiology · Bentonville, ARNPI 1952615007
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,226 of the $12,577 with a category attached, or 81.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,717 and has fallen 59.4% since, to $1,102 in 2025.
Across 241 payments — averaging $52.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Boston Scientific$2K
- Inari Medical, Inc.$2K
- Abiomed$781
- Philips North America LLC$729
- Stryker$683
- plus $4K from 24 others
What the payments were for
- Travel & lodging$2,33919%
- Food & beverage$10,22681%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 33 | $2,976 |
| Boston Scientific | 55 | $2,045 |
| Inari Medical, Inc. | 32 | $1,734 |
| Abiomed | 10 | $781 |
| Philips North America LLC | 19 | $729 |
| Stryker | 20 | $683 |
| Baylis Medical Company Inc | 6 | $681 |
| Amgen(2 entities) | 8 | $371 |
| Terumo Medical Corporation | 3 | $324 |
| Medtronic(2 entities) | 5 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $241 |
| Penumbra, Inc. | 2 | $218 |
| Shockwave Medical, Inc | 6 | $199 |
| Cardiovascular Systems Inc. | 3 | $166 |
| Elutia, Inc. | 10 | $160 |
| Cardinal Health 200 LLC | 1 | $124 |
| Amarin Pharma, Inc. | 1 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $120 |
| AstraZeneca | 3 | $114 |
| Surmodics, Inc. | 1 | $113 |
| Cordis US CORP. | 4 | $92 |
| Boehringer Ingelheim | 1 | $91 |
| Novartis | 3 | $53 |
| Bard Peripheral Vascular, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $22 |
| Asahi Intecc USA, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Emboshield NAV6 system$1,676
- FLOWTRIEVER CATHETER, S$1,494
- CT THROMBECTOMY SYSTEM KIT$982
- Impella$579
- VersaCross Access Solution$522
- FlowTriever$396
- ClotTriever$268
- Xact carotid stent system$246
- EMBLEM MRI S-ICD$149
- Heartrail$148
- ANGIO-SEAL$148
- Reveal LINQ$140
- KRYSTEXXA$125
- EMBLEM$123
- Micra$123
- Vascepa$122
- Turbo Power$121
- (6578) Visions 018$121
- NURTEC ODT$120
- CardioMEMS HF System$114
How this compares
$12,577 in reported general payments places this provider in the 70th percentile of 89 interventional cardiology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 582 | $456,350 |
| XareltoRivaroxaban | 174 | $143,697 |
| EntrestoSacubitril/Valsartan | 124 | $116,703 |
| BrilintaTicagrelor | 48 | $25,277 |
| Repatha SureclickEvolocumab | 27 | $24,543 |
| FarxigaDapagliflozin Propanediol | 13 | $13,349 |
| Praluent PenAlirocumab | 13 | $6,044 |
| Ranolazine ErRanolazine | 67 | $5,987 |
| Dofetilide | 11 | $5,172 |
| Midodrine Hcl | 34 | $4,576 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 213 | $4,331 |
| Atorvastatin Calcium | 511 | $4,038 |
| Metoprolol Succinate | 260 | $2,860 |
| Carvedilol | 490 | $2,278 |
| Losartan Potassium | 233 | $1,993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $22 | $143,697174 claims |
| NovartisEntresto | $53 | $116,703124 claims |
| AstraZenecaBrilinta, Farxiga | $114 | $38,62661 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 89 interventional cardiology providers in Arkansas.
Other interventional cardiology in Bentonville
- Maria BaldasareBentonville$9K
- Gaurav DharLittle Rock$206K
- Ernesto Ruiz-RodriguezLittle Rock$153K
- Vasili LendelLittle Rock$86K
- Thomas WattsLittle Rock$68K
- Vijay RajaLittle Rock$46K
- Lena AwarJonesboro$43K
- Zubair AhmedFayetteville$36K
- Stephen BroughtonLittle Rock$34K
- Hani TurkmaniNorth Little Rock$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.